Novus launches world's leading protease feed enzyme, CIBENZA DP100

In China this week, Novus's Sustainable Feed Raw Material Application lecture series kicked off with the launch of the world's leading protease feed enzyme, CIBENZA® DP100, into the Chinese market.

Protease enzymes are scientifically proven to significantly increase the availability of dietary amino acids to monogastric animals. Formulating diets with CIBENZA DP100 allows producers to enhance the digestibility of a broad range of protein sources, ranging from highly digestible soybean meal to feather meal, which falls at the other end of the digestibility spectrum. In addition to improved nutrient utilization, CIBENZA DP100 supports a consistently high growth performance, improves flock uniformity, optimizes gut health and ultimately reduces feed ration costs.

Novus International, Inc. hosted the lecture series in Xi'an and Hangzhou, China where industry leaders, academics and members of Novus's research and development team discussed the advantages of using cutting-edge enzyme technologies to support operations. CIBENZA DP100 has proven itself to not only optimize animal performance, but reduce feed costs as well, making it a valuable economic tool for producers.

The forum included opening remarks from Flemming Mahs, Novus general manager for Northeast Asia, as well as prominent professors from China Agriculture University. Key speakers shared their personal testimonies about the effectiveness of CIBENZA DP100, research results and the importance of strategic enzyme application in animal production. Novus's longstanding dedication to poultry science and industry-leading research in animal nutrition was also highlighted at the series.

"The Sustainable Feed Raw Material Application lecture series was a momentous event and extraordinarily successful," commented Mahs. "Novus is passionate about providing sustainable enzyme solutions to the animal feed industry, and it was great to see this initiative being so well-received among the forum's participants."



Novus International, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Study suggests Alzheimer’s disease diagnosis is associated with higher levels of soluble ACE2 in the human brain